Monday, June 26, 2017 10:29:36 AM
I'm curious how quickly these drugs work, compared to acyclovir. I didn't see that in the poster. I think they only showed results at 6 days. Also, they treated with the various ShinglesCides before infecting the cells. I would have liked to have seen the effect of treatment after infection. If somehow they could show percent of infected cells that would have been great, too.
This cell culture is not a perfect system. If nanoviricides truly act only outside of cells, then it would appear these drugs are preventing virus from infecting the cells. In humans, the drugs would potentially act to prevent additional cells from being infected (spread to other skin cells and to other neurons). Ideally would start with a few infected cells in a dish and measure how well the drugs block infection of additional cells. Could take the infected cells, wash them, and add them to uninfected cells, then see how well the drug works to prevent infection in additional cells.
By the way, the "optimization problem" seems like it can be solved the way most other drug discovery is done, by screening lots of compounds - which NNVC did, and can continue to do.
Also, it's nice to see confirmation this was all done "in-house" by NNVC and AllExcel scientists (probably almost all by Friedrich).
I'm looking forward to some critical evaluation of this work, such as quibbling about what does "5 times better than acyclovir" really mean?
Overall it's a nice solid foundation of work.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM